Ganga Pharmaceuticals Current Share Price | Ganga Pharmaceuticals Stock Screener
GANGAPHARM
Pharmaceuticals
Ganga Pharmaceuticals Current Stock Price Today
Track the current Ganga Pharmaceuticals share price and stock price live with TickJournal's free stock screener.
Analyse GANGAPHARM price movement history and track historical price performance.
Use the Ganga Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Ganga Pharmaceuticals Market Cap
₹7.10 Cr.
GANGAPHARM P/E Ratio (TTM)
488.20
Ganga Pharmaceuticals P/B Ratio
0.91
EPS (TTM)
₹0.17
Dividend Yield
-
Debt to Equity
0.20
GANGAPHARM 52 Week High
-
Ganga Pharmaceuticals 52 Week Low
-
Operating Margin
-2.00%
Profit Margin
-
GANGAPHARM Revenue (TTM)
₹2.00
EBITDA
-
Net Income
-
Total Assets
₹10.00
Total Equity
₹8.00
Ganga Pharmaceuticals Current Share Price Chart
Track the current Ganga Pharmaceuticals share price and stock price with an interactive chart. Analyse GANGAPHARM price trends, trading volume, historical performance, and volatility across different timeframes — the complete Ganga Pharmaceuticals stock quote in one place.
Ganga Pharmaceuticals Company Profile - Fundamental Screener
Screen Ganga Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for GANGAPHARM shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE615T01017
Ganga Pharmaceuticals Balance Sheet Screener
Screen GANGAPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Current Assets | 8 | 7 | 6 | 5 | 5 | 5 | 4 | 4 | 5 | 4 |
| Fixed Assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 8 | 7 | 7 | 6 | 5 | 5 | 5 | 5 | 5 | 5 |
| Share Capital | 6 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves & Surplus | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Ganga Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Ganga Pharmaceuticals income statement and profit fundamentals.
Analyze GANGAPHARM quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Ganga Pharmaceuticals share price evaluation.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 |
| Expenses | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 2 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Operating Profit % | -2.00% | 1.00% | -4.00% | 2.00% | 0.00% | 2.00% | 1.00% | 13.00% | 12.00% | 11.00% | 10.00% | 12.00% | 9.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS | 0.10 | 0.17 | 0.16 | 0.11 | 0.10 | 0.09 | 0.05 | 0.46 | 0.46 | 0.23 | 0.18 | 0.12 | 0.00 |
Ganga Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen GANGAPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Investing Activities | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | -1 |
| Financing Activities | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ganga Pharmaceuticals Shareholding Pattern Screener
See Ganga Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Ganga Pharmaceuticals promoter holding and ownership changes for GANGAPHARM on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Jul | 2025-Sept | 2024-Mar | 2024-Sept | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 50.91% | 56.02% | 50.91% | 50.91% | 50.91% | 56.02% | 56.02% | 66.71% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 35.32% | 35.07% | 35.46% | 35.46% | 35.32% | 35.40% | 35.23% | 31.91% |
| Other Holding | 13.77% | 8.91% | 13.63% | 13.63% | 13.77% | 8.58% | 8.75% | 1.38% |
| Shareholder Count | 365 | 368 | 367 | 367 | 366 | 363 | 365 | 356 |
Ganga Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Ganga Pharmaceuticals dividend history with payout and yield data.
View Ganga Pharmaceuticals dividend details including ex-dates and amounts for GANGAPHARM stock.
Ganga Pharmaceuticals Stock Index Membership
See which indices include Ganga Pharmaceuticals stock.
Check GANGAPHARM index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Ganga Pharmaceuticals Market Events Screener - Corporate Actions
Get Ganga Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Ganga Pharmaceuticals stock events that may affect GANGAPHARM share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-21 | 2026-05-21 | Quarterly Result Announcement | NA | 0.00% |
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | 0.00% |
| 2025-09-20 | 2025-09-20 | Annual General Meeting | NA | 0.00% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 0.00% |
| 2024-11-08 | 2024-11-08 | Quarterly Result Announcement | NA | 0.00% |
| 2024-09-25 | 2024-09-25 | Annual General Meeting | NA | -20.67% |
| 2024-01-04 | 2024-01-04 | Extraordinary General Meeting | NA | 88.72% |
Ganga Pharmaceuticals Competitors Screener - Peer Comparison
Screen GANGAPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 449,539 | 37.28 | 61,674 | 12.69% | 11,565 | 34.94 |
| Divis Laboratories | 227,719 | 77.10 | 11,067 | 13.95% | 2,568 | 71.94 |
| Torrent Pharmaceuticals | 189,499 | 86.36 | 13,886 | 20.34% | 2,138 | 50.31 |
| Cipla | 115,885 | 34.42 | 29,045 | 2.24% | 3,870 | 44.50 |
| Zydus Life Science | 112,879 | 24.59 | 27,658 | 17.64% | 5,026 | 49.84 |
| Lupin | 101,821 | 18.61 | 29,039 | 26.75% | 5,356 | 34.85 |
| Dr Reddys Laboratories | 98,992 | 31.25 | 35,059 | 3.90% | 4,158 | 46.88 |
| Laurus Labs | 98,308 | 89.15 | 6,868 | 22.01% | 890 | 64.41 |
| Mankind Pharma | 98,029 | 47.94 | 14,636 | 14.85% | 1,938 | 38.70 |
| Aurobindo Pharma | 94,189 | 25.43 | 34,145 | 5.56% | 3,503 | 56.48 |
Ganga Pharmaceuticals Company Announcements - News Screener
Screen GANGAPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-07-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-28 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-21 | Appointment Of Secretarial Auditor | - |
| 2026-05-21 | Appointment Of Internal Auditor | - |
| 2026-05-21 | Audited Financial Results Of The Company For The Half Year And Financial Year Ended March 31 2026. | - |
| 2026-05-21 | Board Meeting Outcome for Outcome Of The Board Meeting Held On May 21 2026 | - |
| 2026-05-14 | Board Meeting Intimation for Board Meeting Intimation Under Regulation 29 The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-04-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-26 | Closure of Trading Window | - |
| 2026-03-16 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-03-10 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-03-10 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-01-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-11-07 | Statement Of Deviation Or Variation Pursuant To Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2025-11-07 | Statement Of Deviation Or Variation Pursuant To Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2025-11-07 | Un-Audited Financial Results Of The Company For The Half Year Ended On September 30 2025. | - |
| 2025-11-07 | Board Meeting Outcome for Held On Friday November 07 2025 | - |
| 2025-11-03 | Board Meeting Intimation for To Consider And Approve The Unaudited Financial Results Of The Company For The Half Year Ended On September 30 2025 | - |
| 2025-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |